Asthma is the most common pulmonary disease in children age 5 to 17 years. Asthma is characterized by chronic airway inflammation and heterogeneous clinical phenotypes. A small proportion of patients (approximately 5% to 10%) diagnosed with severe asthma are unable to achieve asthma control even with intensive therapy. Severe asthma in children is characterized by poor asthma control, uncontrolled symptoms, poor quality of life, disrupted school-related activities and increased risk of exacerbations, health care use, and morbidities due to asthma. Several new biologic agents targeting the mediators of asthma inflammation that are now approved are likely to improve asthma outcomes in children with severe asthma. This article outlines the various biologic agents currently approved for use in children. [Pediatr Ann. 2021;50(5):e206-e213.].

中文翻译：

---

儿童严重哮喘的治疗：生物制剂怎么样？

哮喘是 5 至 17 岁儿童最常见的肺部疾病。哮喘的特征是慢性气道炎症和异质的临床表型。一小部分被诊断为重度哮喘的患者（约 5% 至 10%）即使采用强化治疗也无法实现哮喘控制。儿童重度哮喘的特点是哮喘控制不佳、症状不受控制、生活质量差、学校相关活动中断以及哮喘恶化、医疗保健使用和发病率增加的风险。几种针对哮喘炎症介质的新型生物制剂现已获批，可能会改善重度哮喘儿童的哮喘预后。本文概述了目前批准用于儿童的各种生物制剂。[小儿安。2021;50(5):e206-e213.]。